Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: 2015

    Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

    20151223_TIME Ph2b Lancet Oncology 2015_PR EN

    Published 23 December 2015
    Categorized as 2015, Press release, TG4010

    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

    Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication

    Published 18 December 2015
    Categorized as 2015, Publication, TG4010

    A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates

    Stephane Leung-Theung-Long, et al. PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication

    Published 24 November 2015
    Categorized as 2015, Publication, TB Program

    TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial

    John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation

    Published 13 November 2015
    Categorized as 2015, Publication, TG4010

    Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development

    20151112 SillaJen_Pexavec_Joint

    Published 12 November 2015
    Categorized as 2015, Pexa-Vec, Press release

    Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection

    20151103 TG1050 FINAL VERSION US

    Published 4 November 2015
    Categorized as 2015, Press release, TG1050

    Transgene Reports Third Quarter 2015 Financial Results

    20151021 PR US Q3 2015 FINAL

    Published 21 October 2015
    Categorized as 2015, Press release

    Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York

    23092015 PR ladenburg conf_EN

    Published 23 September 2015
    Categorized as 2015, Press release

    Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

    Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication

    Published 18 September 2015
    Categorized as 2015, Publication, TG1050

    Transgene Reports Financial Results for First Six Months of 2015 (interim report)

    20150910 – PR 2015 H1 results final

    Published 10 September 2015
    Categorized as 2015, Press release

    Posts navigation

    Page 1 … Page 3 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo